Company intelligence / Profile preview

NeuroTrigger

Raanana, Tel Aviv District, Israelnt-med.com ↗

Ownership: Private
Development stage: Other

Overview

NeuroTrigger has received FDA 510(k) clearance for its non-invasive NTB muscle stimulation system, indicated for the prevention or retardation of disuse atrophy and muscle reeducation to maintain/increase range of motion. The company is conducting further clinical trials in the US and UK to expand labeling claims, including use in facial paralysis patients.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapyWearable technology
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on NeuroTrigger.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroTrigger.

Explore the full profile